Company Overview and News

 
TGXSF / Tigenix Sa AMENDMENT NO. 2 TO SCHEDULE 14D-9

2018-05-21 sec.gov
Amendment No. 2 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-05-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX

 
TGXSF / Tigenix Sa AMENDMENT NO. 1 TO SCHEDULE 14D-9

2018-05-14 sec.gov
Amendment No. 1 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
TGXSF / Tigenix Sa 20-F/A

2018-05-11 sec.gov
As filed with the Securities and Exchange Commission on May 11, 2018

 
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-05-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX

 
TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018

2018-05-08 globenewswire
TiGenix Limited liability company that makes or has made a public call on savings Romeinse straat 12 box 2 3001 Leuven VAT BE 0471.340.123 RLE Leuven

 
TiGenix: OPROEPING TOT DE GEWONE ALGEMENE VERGADERING DIE ZAL WORDEN GEHOUDEN OP 7 JUNI 2018

2018-05-08 globenewswire
TiGenix Naamloze vennootschap die een openbaar beroep doet of heeft gedaan op het spaarwezen Romeinse straat 12 bus 2 3001 Leuven BTW BE 0471.340.123 RPR Leuven

 
TGXSF / Tigenix Sa SC 14D9

2018-04-30 sec.gov
SC 14D9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <

 
TGXSF / Tigenix Sa SC14D9C

2018-04-27 sec.gov
SECURITIES AND EXCHANGE C

 
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-04-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX

 
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-04-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX

 
TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018

2018-04-27 globenewswire
Leuven (BELGIUM) - April 27, 2018, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces the publication of the prospectus and response memorandum in relation to the previously announced voluntary and conditional public takeover bid by Takeda Pharmaceutical Company Limited ("Takeda") to acquire TiGenix (the "Bid").

 
TiGenix: Publicatie van prospectus en memorie van antwoord voor het overnamebod van Takeda dat begint op 30 april 2018

2018-04-27 globenewswire
Publicatie van prospectus en memorie van antwoord voor het overnamebod van Takeda dat begint op 30 april 2018

 
TiGenix: Publication du prospectus et mémoire en réponse pour l'offre publique d'acquisition de Takeda débutant le 30 avril 2018

2018-04-27 globenewswire
Publication du prospectus et mémoire en réponse pour l'offre publique d'acquisition de Takeda débutant le 30 avril 2018

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 88675R109